The strong H1 beat and maintained guidance at the upper end are clear positives, but the ATM facility creates potential dilution. Traders should watch for the prospectus supplement filing to gauge the pace and size of any ATM sales, which could cap near-term upside. The PDUFA date for Pixclara on September 11, 2026, is a key catalyst.
Price Chart
Executive Summary
Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a loss of $2M in H1 2025, driven by strong commercial performance and a $40M non-refundable payment from Regeneron. The company reaffirmed FY 2026 revenue guidance at the upper end of $950M-$970M and expects total revenue and other income to exceed $1B, while also establishing an ATM facility for potential equity issuance. The strong beat on profitability and maintained guidance are positive, but the ATM facility introduces dilution overhang, tempering the overall bullish signal.
Key Financial Metrics
Key Facts
- H1 2026 revenue of $477M, up 22% YoY from $390M
- Net profit of $38M vs loss of $2M in H1 2025
- Adjusted EBITDA of $52M, up 146% YoY from $21M
- Precision Medicine segment revenue up 27% YoY with gross margin of 65%
- FY 2026 revenue guidance reaffirmed at upper end of $950M-$970M, total revenue and other income expected to exceed $1B
- Established an ATM facility to sell up to undisclosed amount of ADSs at market prices
- Cash balance of $252M as of June 30, 2026
- Entered strategic collaboration with Regeneron, receiving $40M initial payment
Financial Impact
Revenue of $477M vs consensus $311.6M (beat by ~53%), net profit of $38M vs consensus EPS of -$0.01 (strong beat). FY guidance of $950M-$970M revenue implies H2 revenue of $473M-$493M.
Risk Factors
- ATM facility could lead to dilution if shares are sold at current market prices
- R&D spending of $124M in H1 (vs $82M in H1 2025) may pressure near-term profitability if revenue growth slows
- BLA resubmission for Zircaix (TLX250-Px) remains pending with FDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access